Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2020

01.01.2020 | Clinical Study

DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy

verfasst von: Yoshie Umemura, Diane Wang, Kyung K. Peck, Jessica Flynn, Zhigang Zhang, Robin Fatovic, Erik S. Anderson, Kathryn Beal, Alexander N. Shoushtari, Thomas Kaley, Robert J. Young

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

It can be challenging to differentiate pseudoprogression from progression. We assessed the ability of dynamic contrast enhanced T1 MRI (DCE-MRI) perfusion to identify pseudoprogression in melanoma brain metastases.

Methods

Patients with melanoma brain metastases who underwent immunotherapy and DCE-MRI were identified. Enhancing lesions ≥  5mm in diameter on DCE-MRI and that were new or increased in size between a week from beginning the treatment, and a month after completing the treatment were included in the analysis. The 90th percentiles of rVp and rKtrans and the presence or absence of hemorrhage were recorded. Histopathology served as the reference standard for pseudoprogression. If not available, pseudoprogression was defined as neurological and radiographic stability or improvement without any new treatment for ≥ 2 months.

Results

Forty-four patients were identified; 64% received ipilimumab monotherapy for a median duration of 9 weeks (range, 1–138). Sixty-four lesions in 44 patients were included in the study. Of these, nine lesions in eight patients were determined to be pseudoprogression and seven lesions were previously irradiated. Forty-four progression lesions and eight pseudoprogression lesions were hemorrhagic. Median lesion volume for pseudoprogression and progression were not significantly different, at 2.3 cm3 and 3.2 cm3, respectively (p = 0.82). The rVp90 was smaller in pseudoprogression versus progression, at 2.2 and 5.3, respectively (p = 0.02), and remained significant after false discovery rate adjustment (p = 0.04).

Conclusions

Pseudoprogression exhibited significantly lower rVp90 on DCE-MRI compared with progression. This knowledge can be useful for managing growing lesions in patients with melanoma brain metastases who are receiving immunotherapy.
Literatur
1.
Zurück zum Zitat Gupta G, Robertson AG, MacKie RM (1997) Cerebral metastases of cutaneous melanoma. Br J Cancer 76(2):256–259CrossRef Gupta G, Robertson AG, MacKie RM (1997) Cerebral metastases of cutaneous melanoma. Br J Cancer 76(2):256–259CrossRef
2.
Zurück zum Zitat Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30(6):515–520CrossRef Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30(6):515–520CrossRef
3.
Zurück zum Zitat Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543CrossRef Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543CrossRef
4.
Zurück zum Zitat Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRef Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420CrossRef
5.
Zurück zum Zitat Lin NU, Lee EQ, Aoyama H et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270–278CrossRef Lin NU, Lee EQ, Aoyama H et al (2015) Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 16(6):e270–278CrossRef
6.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–247.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–247.CrossRef
7.
Zurück zum Zitat Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58(8):1297–1306CrossRef Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58(8):1297–1306CrossRef
8.
Zurück zum Zitat Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ (2015) Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 36(5):877–885CrossRef Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ (2015) Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. AJNR Am J Neuroradiol 36(5):877–885CrossRef
9.
Zurück zum Zitat Young RJ, Gupta A, Shah AD et al (2013) MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37(1):41–49CrossRef Young RJ, Gupta A, Shah AD et al (2013) MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging 37(1):41–49CrossRef
10.
Zurück zum Zitat Patel P, Baradaran H, Delgado D et al (2017) MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro-oncology 19(1):118–127CrossRef Patel P, Baradaran H, Delgado D et al (2017) MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro-oncology 19(1):118–127CrossRef
11.
Zurück zum Zitat Wang S, Martinez-Lage M, Sakai Y et al (2016) Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 37(1):28–36CrossRef Wang S, Martinez-Lage M, Sakai Y et al (2016) Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. AJNR Am J Neuroradiol 37(1):28–36CrossRef
12.
Zurück zum Zitat Thomas AA, Arevalo-Perez J, Kaley T et al (2015) Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol 125(1):183–190CrossRef Thomas AA, Arevalo-Perez J, Kaley T et al (2015) Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol 125(1):183–190CrossRef
13.
Zurück zum Zitat Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197CrossRef Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197CrossRef
14.
Zurück zum Zitat Jung SC, Yeom JA, Kim JH et al (2014) Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 35(6):1103–1110CrossRef Jung SC, Yeom JA, Kim JH et al (2014) Glioma: application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading. AJNR Am J Neuroradiol 35(6):1103–1110CrossRef
15.
Zurück zum Zitat Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson imaging 10(3):223–232CrossRef Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson imaging 10(3):223–232CrossRef
16.
Zurück zum Zitat Arevalo-Perez J, Thomas AA (2015) T1-Weighted dynamic contrast-enhanced MRI as a noninvasive biomarker of epidermal growth factor receptor vIII status. AJNR Am J Neuroradiol 36(12):2256–2261CrossRef Arevalo-Perez J, Thomas AA (2015) T1-Weighted dynamic contrast-enhanced MRI as a noninvasive biomarker of epidermal growth factor receptor vIII status. AJNR Am J Neuroradiol 36(12):2256–2261CrossRef
17.
Zurück zum Zitat Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125(1):17–23CrossRef Colaco RJ, Martin P, Kluger HM, Yu JB, Chiang VL (2016) Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 125(1):17–23CrossRef
18.
Zurück zum Zitat Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16(15):e534–542CrossRef Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16(15):e534–542CrossRef
19.
Zurück zum Zitat Pruitt AA (2015) Medical management of patients with brain tumors. Continuum (Minneap Minn). 2015;21(2 Neuro-oncology):314–331. Pruitt AA (2015) Medical management of patients with brain tumors. Continuum (Minneap Minn). 2015;21(2 Neuro-oncology):314–331.
Metadaten
Titel
DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy
verfasst von
Yoshie Umemura
Diane Wang
Kyung K. Peck
Jessica Flynn
Zhigang Zhang
Robin Fatovic
Erik S. Anderson
Kathryn Beal
Alexander N. Shoushtari
Thomas Kaley
Robert J. Young
Publikationsdatum
01.01.2020
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-019-03379-6

Weitere Artikel der Ausgabe 2/2020

Journal of Neuro-Oncology 2/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.